Efeito de Lactobacillus casei e Bifidobacterium breve na diarréia associada a antimicrobiano : experimento clínico duplo-cego

• Autor(a) principal: Souza, Daniela Nogueira Prado de
• Data de Publicação: 2010
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFU
• Texto Completo: https://repositorio.ufu.br/handle/123456789/12673
• topic: Bifidobacterium breve; Diarréia associada a antimicrobiano; Probiotics; Antibioticassociated diarrhea; CNPQ::CIENCIAS DA SAUDE

Antibiotic-associated diarrhea (AAD) is characterized as that developed after the start of antibiotic therapy or up to six to eight weeks after completion of treatment. It is considered an important side effect of this class of drugs and occurs in approximately 5% to 25% of patients on antimicrobials. The aim of this study was to investigate the effect of the use of probiotics in the treatment of DAA. The study included patients hospitalized with diarrhea developed during the use or up to seven days after the suspension of antimicrobial use. The patients were randomized blindly to receive standardized diet associated, three times a day, the probiotic (Lactobacillus casei and Bifidobacterium breve) or placebo. For the experimental and control group, respectively, the average time of treatment was 5.06 ± 2.18 and 5.49 ± 3.17 days (p=0.95) and the mean duration of diarrhea, among those who healed, was 4.87 ± 2.13 and 4.52 ± 2.55 days (p=0.36). Four patients (11.43%) who received probiotics and ten (28.57%) of those who received placebo were not cured and no cure rates and relapse rates were similar between groups. Seven patients of probiotic group and seven of placebo group, showed ,in addition to diarrhea, bloating and / or abdominal cramps and / or vomiting (p=1.00). In this light, it is concluded that L. casei associated with B. breve, in the administered dosage and frequency, have no effect on the DAA.